SERUM ERYTHROPOIETIN (SEPO) TESTING, LEVELS, AND SUBSEQUENT TREATMENT PATTERNS FOR TRANSFUSION-DEPENDENT PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

被引：0
|
作者：
Gerds, A. [1 ]
Binder, G. [2 ]
Fliss, A. [2 ]
McGuire, M. [2 ]
Hawthorne, S. [3 ]
King-Concialdi, K. [3 ]
DiBonaventura, M. [3 ]
机构：
[1] Cleveland Clin, Cleveland, OH USA
[2] Celgene Corp, Summit, NJ USA
[3] Kantar Hlth, New York, NY USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1917
引用
收藏
页码：772 / 773
页数：2
相关论文
共 50 条
  • [1] Serum erythropoietin (sEPO) testing and treatment patterns for transfusion-dependent (TD) patients (pts) with myelodysplastic syndromes (MDS).
    Gerds, Aaron Thomas
    Binder, Gary
    Fliss, Albert
    McGuire, Michael
    Hawthorne, Stephanie Marie
    King-Concialdi, Kristen
    DiBonaventura, Marco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Cost of transfusion-dependent myelodysplastic syndromes (MDS) in Germany
    Kuehne, F.
    Mittendorf, T.
    Voelkl, M.
    Lipp, R.
    Germing, U.
    Vioni-Niemeyer, A.
    von der Schulenburg, J. M.
    LEUKEMIA RESEARCH, 2007, 31 : S111 - S111
  • [3] Cost of transfusion-dependent myelodysplastic syndromes (MDS) in Germany
    Kuehne, C.
    Mittendorf, T.
    Voelk, M.
    Lipp, R.
    Gerning, U.
    Vionniemeyer, A.
    von der Schulenberg, J. M. Graf
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 547 - 547
  • [4] Cost of transfusion-dependent myelodysplastic syndromes (MDS) in Germany
    Kuehne, F. C.
    Mittendorf, T.
    Voelkl, M.
    Lipp, R.
    Germing, U.
    Vioni-Niemeyer, A.
    Von der Schulenburg, J. M.
    VALUE IN HEALTH, 2007, 10 (06) : A282 - A282
  • [5] LEVELS OF TRANSFUSION BURDEN AND ASSOCIATED COSTS FOR PATIENTS WITH TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES
    DeZern, A. E.
    Binder, G.
    Rizvi, S.
    Corvino, F. A.
    Arikian, S. R.
    Surinach, A.
    Lee, J.
    Smith, B. D.
    HAEMATOLOGICA, 2016, 101 : 245 - 245
  • [6] Do ESAs Reduce Transfusion Need among Transfusion-Dependent Myelodysplastic Syndromes (MDS) Patients?
    Smith, Sheila R. Weiss
    Sato, Masayo
    Baer, Maria R.
    Ke, Xuehua
    Gore, Steven D.
    Davidoff, Amy
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 : S282 - S283
  • [7] Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes
    Delforge, Michel
    Selleslag, Dominik
    Triffet, Agnes
    Mineur, Philippe
    Bries, Greet
    Graux, Carlos
    Trullemans, Fabienne
    MacDonald, Karen
    Abraham, Ivo
    Pluymers, Wim
    Ravoet, Christophe
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 655 - 666
  • [8] Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes
    Michel Delforge
    Dominik Selleslag
    Agnès Triffet
    Philippe Mineur
    Greet Bries
    Carlos Graux
    Fabienne Trullemans
    Karen MacDonald
    Ivo Abraham
    Wim Pluymers
    Christophe Ravoet
    Annals of Hematology, 2011, 90 : 655 - 666
  • [9] Cost-effectiveness of lenalidomide in the treatment of patients with transfusion-dependent myelodysplastic syndromes (MDS) in the United States.
    Goss, TF
    Szende, A
    Brueckner, J
    Wang, M
    Schaefer, C
    List, AF
    BLOOD, 2005, 106 (11) : 388A - 389A
  • [10] Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
    Gerds, Aaron T.
    Gupta, Shaloo
    Binder, Gary
    Sekeres, Mikkael A.
    Nazha, Aziz
    Carraway, Hetty E.
    Hawthorne, Stephanie
    King-Concialdi, Kristen
    McGuire, Michael
    BLOOD, 2016, 128 (22)
12345